CD274 and cancer: Previous studies have shown that the expression level of PD-L1 is a potential biomarker for predicting the response to ICIs in various cancers (27, 28); however, the role of the expression level of PD-L1 in SCLC in predicting the efficacy of ICIs is not obvious (29).